Industry Leaders to Explore Potential of AI in Contrast-Enhanced MRIs.


Industry Leaders to Explore Potential of AI in Contrast-Enhanced MRIs

MILAN, Sept. 21, 2023 /PRNewswire/ -- Bracco Imaging S.p.A., a global leader in diagnostic imaging, and Subtle Medical, Inc., a leading innovator in artificial intelligence (AI)-powered imaging, have signed an agreement global in the field of magnetic resonance imaging (MRI). This global agreement will begin primarily in the United States, where Bracco Imaging distributes its portfolio of products and services through its subsidiary, Bracco Diagnostics Inc.

Contrast-enhanced MRI involves the use of contrast agents to highlight specific tissues or abnormalities, providing better visualization and more detailed information. Exploring and harnessing the power of AI in this context could lead to more accurate and efficient image interpretation, improved diagnostic capabilities, and optimized patient care. Through this strategic partnership, Bracco Imaging and Subtle Medical can leverage each other's intellectual property to move toward achieving these ambitious goals.

"The combination of Bracco's expertise in contrast imaging and Subtle Medical's deep learning technology, when applied to MRI imaging, will undoubtedly benefit physicians and their patients," said Fulvio Renoldi Bracco, vice president and CEO of Bracco Imaging S.p.A. "Through this partnership, we will strive to redefine the boundaries of diagnostic accuracy and efficiency, unlocking new possibilities and bringing additional value to our already unique MRI portfolio."

"Subtle Medical is pleased to partner with a global leader in contrast development and commercialization like Bracco," said Enhao Gong, CEO of Subtle Medical, Inc. "This agreement represents an important milestone for both companies as we join forces to empower to medical professionals and improve outcomes for patients around the world with Subtle Medical's platform and innovative suite of AI products for MRI and more."

About Bracco Imaging

Bracco Imaging S.p.A., part of the Bracco Group, is a leading global diagnostic imaging provider. Headquartered in Milan, Italy, Bracco Imaging develops, manufactures and markets diagnostic imaging agents and solutions. Offers a portfolio of products and solutions for all key diagnostic imaging modalities: X-ray imaging (including computed tomography-CT, interventional radiology and cardiac catheterization), magnetic resonance imaging (MRI), contrast-enhanced ultrasound (CEUS) and nuclear medicine through radioactive tracers and novel PET imaging agents to inform clinical management and guide the care of cancer patients in areas of unmet medical need. Our continually evolving portfolio is completed with a range of medical devices, advanced delivery systems and dose management software. In 2019, Bracco Imaging enriched its product portfolio by expanding the range of oncology nuclear imaging solutions in the urology and other specialties segment with the acquisition of Blue Earth Diagnostics. In 2021, Bracco Imaging established Blue Earth Therapeutics as an independent, cutting-edge biotechnology company dedicated to advancing next-generation targeted radiation therapy to treat cancer patients. Visit for more information.

About Subtle Medical

Subtle Medical is a leading global provider of AI-powered technology for faster, safer and smarter medical imaging. It has been named a CB Insights GenAI 50 company and has twice been named a CB Insights Top AI 100 company and Digital Health 150. The company's cutting-edge solutions optimize imaging workflows, improving productivity and the patient experience. By harnessing the power of artificial intelligence, Subtle Medical aims to revolutionize medical imaging and transform the future of healthcare. For more information, visit or email

Contact for media: Micaela Colamasi Bracco Imaging PR manager 39 3482314362

Anna Menyhart-BorroniResponsable de Marketing Subtle Medical 1 501-766-2662

Logo -

View original content: